HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 553-561

  Wilking, Ulla ^a   Karlsson, Eva ^a,c   Skoog, Lambert ^a   Hatschek, Thomas ^a,b   Lidbrink, Elisabet ^a,b   Elmberger, Goran ^a   Johansson, Hemming ^a   Lindström, Linda ^a   Bergh, Jonas ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Karlstad Hospital   (Sweden)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Breast cancer; HER2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE; BONE MARROW; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PLEURA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78650986693     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1029-2     Document Type: Article

References (30)

1. SJ Ross JA Fletcher GP Linette 2003 The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 307 325 1:CAS:528:DC%2BD3sXmvFSqt74%3D 10.1634/theoncologist.8-4-307 12897328 (Pubitemid 36929717)
2. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene Science 235 4785 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
3. DJ Slamon B Leyland-Jones S Shalk, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2/neu/NEU for metastatic breast cancer that overexpresses HER2/neu/NEU N Engl J Med 44 11 783 792 10.1056/ NEJM200103153441101 (Pubitemid 32222155)
4. Marty M, Cognetti F, Maraninchi D et al (2001) Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor-2 positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 9: 4265-4274
5. Slamon D, Eiermann W, Robert N, Pienowski T, Martin M, Rolski J et al (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. SABCS (abstract 62)
6. L Ryden M Haglund P Bendahl, et al. 2009 Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer-a national survey performed at pathology departments in Sweden Acta Oncol 48 860 866 19353340
7. R MacFarlane C Speers H Masoudi, et al. 2008 Molecular change in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue micro array series Proc Am Soc Clin Oncol 44 26 (abstract 1000)
8. EE Lower E Glass 2009 Blau B HER-2/neu expression in primary and metastatic breast cancer Breast Cancer Res Treat 113 301 306 1:CAS:528:DC%2BD1MXhsVKntA%3D%3D 10.1007/s10549-008-9931-6 18273700
9. Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (e-print)
10. S Meng D Tripathy S Shete, et al. 2004 HER-2 gene amplification can be acquired as breast cancer progresses PNAS 101 25 9393 9398 1:CAS:528: DC%2BD2cXltlKjsL4%3D 10.1073/pnas.0402993101 15194824 (Pubitemid 38812885)
11. H Yaziji LC Goldstein TS Barry, et al. 2004 HER2 amplification ratios in breast cancer using parallel tissue based methods JAMA 291 1972 1977 1:CAS:528:DC%2BD2cXjs1ajtrk%3D 10.1001/jama.291.16.1972 15113815 (Pubitemid 38544278)
12. L McShane D Altman W Sauerbrei, et al. 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 36 9067 9072 10.1200/JCO.2004.01.0454 16172462
13. JR Landis GG Koch 1977 An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers Biometrics 33 2 363 374 1:STN:280:DyaE2s3it1ansA%3D%3D 10.2307/2529786 884196
14. D Schoenfeld 1982 Partial residuals for the proportional hazards regression model Biometrika 69 239 241 10.1093/biomet/69.1.239
15. E Mittendorf Y Wu M Scaltriti, et al. 2009 Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 23 7381 7388 1:CAS:528:DC%2BD1MXhsFSnu7rL 10.1158/1078-0432.CCR-09-1735 19920100
16. T Fehm G Gebauer W Jäger 2002 Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients Breast Cancer Res Treat 75 2 97 106 1:CAS:528:DC%2BD38XlvFSqurk%3D 10.1023/A:1019601022456 12243512 (Pubitemid 34994945)
17. D Pectasides A Gaglia 2006 HER2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy Anticancer Res 26 1B 647 653 1:CAS:528: DC%2BD28Xhs1ahs7s%3D 16739334
18. D Gancberg A Di Leo F Cardoso, et al. 2002 Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 1036 1043 1:STN:280:DC%2BD38vitFWgtQ%3D%3D 10.1093/annonc/mdf252 12176781
19. Franco A, Col N (2004) Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. In: Perry M (ed) 40th annual meeting of the ASCO, New Orleans, LA, 11 pp (abstract 539)
20. E Munzone G Curigliano A Rocca, et al. 2006 Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy Breast Cancer Res 8 R4 10.1186/bcr1366 16417653 (Pubitemid 44644835)
21. A Lipton K Leitzel SM Ali, et al. 2005 Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy Cancer 104 2 257 263 1:CAS:528:DC%2BD2MXnslymurw%3D 10.1002/cncr.21202 15952182 (Pubitemid 40993251)
22. G Pauletti RongH Danekar, et al. 2000 Assessment of methods for tissues-based detection of the HER-2/neu alteration in human breast cancer: direct comparison of fluorescence in situ hybridization and immunohistochemistry J Clin Oncol 18 21 3651 3664 1:CAS:528:DC%2BD3cXot1antrg%3D 11054438
23. PC Roche VJ Suman RB Jenkins, et al. 2002 Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J Natl Cancer Inst 94 11 855 857 12048274
24. AC Wolf 2007 American society of clinical oncology/college of American pathologists guideline < recommendations for human epidermal growth receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 10.1200/JCO.2006.09.2775 (Pubitemid 350003059)
25. JM Wu MJ Fackler MK Halushka, et al. 2008 Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 7 1938 1946 1:CAS:528:DC%2BD1cXkt1aktbg%3D 10.1158/1078-0432.CCR-07-4082 18381931 (Pubitemid 351551102)
26. PH Cottu J Asselah M Lae, et al. 2008 Intratumoral heterogeneity of HER-2/neu expression and its consequences for the management for advanced breast cancer Ann Oncol 19 596 597
27. J Andersson B Linderholm J Bergh G Elmberger 2004 HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components Appl Immunohistochem Mol Morphol 12 1 14 20 15163013
28. G Ottesen J Christensen J Larsen, et al. 2000 Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy Breast Cancer Res Treat 60 3 219 226 1:STN:280:DC%2BD3M%2Fjtl2isw%3D%3D 10.1023/A:1006453420088 10930109 (Pubitemid 30440537)
29. T Norberg S Klaar G Kärf H Nordgren L Holmberg J Bergh 2001 Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort Cancer Res 61 22 8317 8321 1:CAS:528:DC%2BD3MXovVShsbc%3D 11719465
30. SP Shah RD Morin J Khattra, et al. 2009 Mutational evolution in a lobular breast cancer tumor profiled at single nucleotide resolution Nature 461 809 913 1:CAS:528:DC%2BD1MXht1Cisb%2FM 10.1038/nature08489 19812674